Biochemistry & Proteomics Group, Department of Chemistry and Biomolecular Science, Clarkson University, Potsdam, NY, USA.
Mood and Anxiety Disorders Program, Mount Sinai School of Medicine, New York, NY, USA.
Adv Exp Med Biol. 2019;1140:585-600. doi: 10.1007/978-3-030-15950-4_35.
Major depressive disorder (MDD) is common. Despite numerous available treatments, many individuals fail to improve clinically. Diagnosis of MDD continues to be commonly accomplished via behavioral rather than biological methods. Biomarkers may provide objective diagnosis of MDD, and could include measurements of genes, proteins, and patterns of brain activity. Proteomic analysis and validation of biomarkers is less explored than other areas of biomarker research in MDD. Mass spectrometry (MS) is a comprehensive, unbiased means of proteomic analysis, which can be complemented by directed protein measurements, such as Western Blotting. Prior studies have focused on MS analysis of several human biomaterials in MDD, including human post-mortem brain, cerebrospinal fluid (CSF), blood components, and urine. Further studies utilizing MS and proteomic analysis in MDD may help solidify and establish biomarkers for use in diagnosis, identification of new treatment targets, and understanding of the disorder. A biomarker or a biomarker signature that facilitates a convenient and inexpensive predictive test for depression treatment response is highly desirable.
重度抑郁症（MDD）很常见。尽管有许多可用的治疗方法，但许多患者的临床症状仍未得到改善。目前，MDD 的诊断通常是通过行为而非生物方法进行的。生物标志物可以为 MDD 提供客观的诊断，包括基因、蛋白质和大脑活动模式的测量。与 MDD 中其他生物标志物研究领域相比，蛋白质组学分析和生物标志物的验证研究较少。质谱（MS）是一种全面、无偏的蛋白质组学分析方法，可以通过Western Blotting 等定向蛋白质测量方法进行补充。先前的研究集中在 MDD 中几种人类生物材料的 MS 分析上，包括人死后的大脑、脑脊液（CSF）、血液成分和尿液。利用 MS 和蛋白质组学分析进行 MDD 的进一步研究，可能有助于为诊断、确定新的治疗靶点以及了解该疾病提供更可靠的生物标志物。一个能够方便且经济地预测抑郁症治疗反应的生物标志物或生物标志物特征，是非常需要的。
